This month, Genentech announced a voluntary recall of the ranibizumab injection (SUSVIMO) ocular implant and associated insertion tool. SUSVIMO, which provides continuous administration of the anti-VEGF (vascular endothelial growth factor A) monoclonal antibody fragment ranibizumab, is approved by the FDA for treatment of wet age-related macular degeneration. According to Genentech,…
